Skip to content

Study · Randomized controlled trial · n = 50 · 2021

5 results

Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.

Li Q, Jia M, Yan Z, Li Q, Sun F, He C, Li Y, Zhou X, Zhang H, Liu X, Bu X, Gao P, He H, Zhao Z, Zhu Z

Journal of the American Heart Association10 Jul 2021Cited by 68 (Europe PMC)

PMID34250817 (opens in a new tab)PMCIDPMC8483500 (opens in a new tab)DOI10.1161/jaha.120.020734 (opens in a new tab)PepBankPUB-34250817
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 12 weeks of liraglutide gave better scores in all cognitive tests than the control group after multivariable adjustment.

    In plain wordsIn adults with type 2 diabetes, liraglutide for 12 weeks gave better thinking test scores than the control group.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedCognitive test scores
    Study

    n = 50

    Comparator
    Control group
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    At 12 weeks, patients in the glucagon-like peptide-1 group acquired better scores in all cognitive tests and showed remarkable improvement in memory and attention (P=0.040) test compared with the control group after multivariable adjustment.
    1 context sentence
    Summary · context
    Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, liraglutide improved the memory and attention test more than the control group at 12 weeks (P=0.040).

    In plain wordsIn adults with type 2 diabetes, liraglutide improved memory and attention more than the control group did.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedMemory and attention test
    Study

    n = 50

    Comparator
    Control group
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    showed remarkable improvement in memory and attention (P=0.040) test compared with the control group after multivariable adjustment.
    1 context sentence
    Summary · context
    Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study.
  3. 03HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes, liraglutide increased activation of the dorsolateral prefrontal cortex and orbitofrontal cortex more than the control group (P=0.0038).

    In plain wordsIn adults with type 2 diabetes, liraglutide increased activity in two frontal brain regions more than the control group did.

    Peptide
    Liraglutide
    Outcome
    IncreasePrefrontal cortex activation (fNIRS)
    Study

    n = 50

    Comparator
    Control group
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with the control group, liraglutide significantly increased activation of the dorsolateral prefrontal cortex and orbitofrontal cortex brain regions (P=0.0038).
    1 context sentence
    Summary · context
    Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study.
  4. 04HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes treated with liraglutide, cognitive scores were significantly correlated with changes in the activated brain regions.

    In plain wordsIn adults with type 2 diabetes on liraglutide, thinking scores were linked to changes in activity of certain brain regions.

    Peptide
    Liraglutide
    Outcome
    Not applicableCorrelation of cognitive scores with brain activation changes
    Study

    n = 50

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After liraglutide treatment, cognitive scores were significantly correlated with changes in these activating brain regions (P<0.05)
    1 context sentence
    Summary · context
    Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study.
  5. 05HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes treated with liraglutide, changes in cognitive function did not correlate with changes in body mass index, blood pressure or glycaemic levels.

    In plain wordsIn adults with type 2 diabetes on liraglutide, changes in thinking scores were not linked to changes in weight, blood pressure or blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeCorrelation of cognitive change with BMI, blood pressure and glycaemia
    Study

    n = 50

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    but no correlation was observed between the changes in cognitive function and changes of body mass index, blood pressure, and glycemic levels.
    1 context sentence
    Summary · context
    Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT03707171

Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

Third Military Medical Universityn = 301 Oct 2018 to 1 May 2019

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 10 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.